

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

FRENCH REPUBLIC

INPI

INSTITUT
NATIONAL DE
LA PROPRIÉTÉ
INDUSTRIELLE

P A T E N T

UTILITY CERTIFICATE - CERTIFICATE OF ADDITION

OFFICIAL COPY

The Director-General of the Institut National de la Propriété Industrielle certifies that the attached document is a true copy of an application for industrial property titleright filed at the Institute.

Drawn up in Paris, 23 DEC. 1999

On behalf of the Director-General of the
Institut National de la Propriété Industrielle
The Patent Department Head

(signature)

Martine PLANCHE

INSTITUT
NATIONAL DE
LA PROPRIÉTÉ
INDUSTRIELLE

REGISTERED OFFICE
26bis, rue de Saint-Petersbourg
75800 PARIS Cédex 08
Telephone: 01 53 04 53 04
Fax: 01 42 93 59 30

INPIINSTITUT NATIONAL DE LA
PROPRIÉTÉ INDUSTRIELLE26 bis, rue de Saint Pétersbourg
75800 Paris Cedex 08

Telephone: 01 53 04 53 04 Telefax: 01 42 93 59 30

PATENT, UTILITY CERTIFICATE

Intellectual Property Code - Book VI

REQUEST FOR GRANTConfirmation of filing by fax ☐

Cerfa

No. 55-1328

This form is to be completed in black ink and in block capitals

Reserved for the INPI		1. NAME AND ADDRESS OF THE APPLICANT OR THE REPRESENTATIVE TO WHOM THE CORRESPONDENCE IS TO BE ADDRESSED	
DATE OF SUBMISSION OF THE DOCUMENTS 14 JAN. 1999		CABINET REGIMBEAU 26, Avenue Kléber 75116 PARIS	
NATIONAL REGISTRATION 99/00,328			
DEPARTMENT OF FILING 75			
DATE OF FILING 14 JAN. 1999			
2. APPLICATION		No. of permanent power of attorney	
Nature of the industrial property right		Correspondent's references	
<input checked="" type="checkbox"/> patent <input type="checkbox"/> divisional application		(illegible)	
→ initial application		Telephone	
<input type="checkbox"/> utility certificate <input type="checkbox"/> conversion of a European patent application <input type="checkbox"/> patent		01 45 00 92 02	
<input type="checkbox"/> utility certificate No. date			
Compilation of the search report <input type="checkbox"/> deferred <input checked="" type="checkbox"/> immediate			
The applicant, as a physical person, asks to pay the fee by instalments <input type="checkbox"/> yes <input type="checkbox"/> no			
Title of the invention (maximum 200 characters)			
Composition for treating obesity and esthetic treatment process			
3. APPLICANT(S)		Legal form	
SIREN No. APE-NAF code		SOCIÉTÉ ANONYME	
Name and forenames (underline the surname) or company name		A CONSEIL D'ADMINISTRATION	
LABORATOIRES ARKOPHARMA			
Nationality/Nationalities French			
Full address(es)		Country	
1ère Avenue 2709, M L I D de CARROS LE BROCC, 06510 CARROS		FR	
If insufficient space, continue on plain paper <input type="checkbox"/>			
4. INVENTOR(S) The inventors are the applicants <input type="checkbox"/> yes <input checked="" type="checkbox"/> no If the answer is no, provide a separate designation			
5. REDUCTION OF THE RATE OF FEES <input type="checkbox"/> requested for the first time <input type="checkbox"/> requested prior to filing; attach copy of the favourable decision			
6. PRIORITY DECLARATION OR APPLICATION FOR THE BENEFIT OF THE FILING DATE OF A PRIOR APPLICATION			
Country of origin		Number	Filing date Nature of the application
7. DIVISIONS previous to the present application		No. date	No. date
8. SIGNATURE OF THE APPLICANT OR REPRESENTATIVE (name and capacity of the signatory - registration No.)		SIGNATURE OF THE RECEIVING OFFICIAL	
(signature) 92-1001		(illegible signature)	
		SIGNATURE AFTER REGISTRATION OF THE APPLICATION AT THE INPI	

INPIINSTITUT
NATIONAL DE
LA PROPRIÉTÉ
INDUSTRIELLE**PATENT, UTILITY CERTIFICATE****DESIGNATION OF THE INVENTOR**

(if the applicant is not the inventor or the sole inventor)

PATENTS ADMINISTRATIVE DIVISION26bis, rue de Saint-Petersbourg
75800 Paris Cédex 08
Tel: 01 53 04 53 04 - Fax: 01 42 93 59 30

NATIONAL REGISTRATION NO.

99/00,328

TITLE OF THE INVENTION:

Composition for treating obesity and esthetic treatment process

THE UNDERSIGNED

LABORATOIRES ARKOPHARMA

1ère Avenue 2709, M L I D de CARROS LE BROC, 06510 CARROS

DESIGNATE(S) AS INVENTOR(S) (surname underlined, forenames, address):

ROMBI Max
Via degli Inglesi, 49
BORDIGHERA 18022, IT**NOTE:** In exceptional cases, the name of the inventor may be followed by that of the company to which he belongs (membership company) when the latter is other than the company which is the applicant or proprietor.

Date and signature(s) of the applicant(s) or of the representative

14 January 1999

CABINET REGIMBEAU

(illegible signature)

92-1001

- 1 -

ORIGINAL

The present invention relates to the general field of treating obesity. The invention is directed in particular toward compositions for the curative and prophylactic treatment of obesity, but it also relates to the esthetic treatment of a human being to enhance his or her figure.

The therapeutic objective as regards obesity is well defined: it is a matter either of allowing the individual to lose a significant amount of weight, or of helping the individual to maintain a weight level which is as low as desired.

Several types of approach have been envisaged to date.

Nutritional approaches are directed toward reducing the supply of energy in the form of foods. This can be achieved either by drastically reducing the energy supplies or by replacing high-energy nutrients with others which are lower in energy: such as indigestible substitute fats, structured triglycerides which are difficult to assimilate or dietary fibers which cannot be assimilated.

The therapeutic approaches may have a variety of targets.

Reducing the food intake may be the first objective. Attempts to reduce the food intake may be made by using anorexigenic substances, whose short-term effects are proven, but whose duration of use is limited on account of adverse side effects. In fact, very few of these products can truly be used and their long-term efficacy remains highly debated. New molecules are undergoing assessment or may do so in the near future, but their value still remains to be shown.

A second objective may be to increase the expenditure of energy by using thermogenic substances which act at the central or peripheral level. The use of these substances still remains limited.

A third objective is to reduce the assimilation of the dietary lipids, or optionally even that of the

- 2 -

carbohydrates. This is a more recent approach, but is gaining in interest. A reduction in the assimilation of the dietary lipids may be obtained either by reducing the activity of the digestive enzymes concerned, or by
5 modifying the properties of the interfaces transporting the lipid molecules, emulsions, vesicles or micelles.

The traditional use of tea is in the form of an infusion, for which the tip of the stems, comprising the last two leaves and the bud, are used. After
10 harvesting, these leaves may be subjected to a fermentation, resulting in a transformation of the chemical substances they contain and in particular the catechols, which corresponds to black tea, or else may be dried immediately, thus giving green tea.

15 Besides catechols, tea contains caffeine, the diuretic effect of which is well known. This diuretic effect is the reason for the traditional use of green tea as a medicinal plant to promote the elimination of water by the kidneys, either in the case of urinary
20 disorders or as a supplement to weight-reducing diets. The presence of caffeine is also the reason for the traditional use of tea in conditions of fatigue (asthenia).

Numerous epidemiological studies carried out on
25 certain populations have clearly demonstrated the beneficial effects of the chronic ingestion of tea, and more particularly of green tea. Thus, the long-term consumption of green tea is thought to be anti-atherogenic on account of its hypocholesterolemiatic
30 effects (Muramatsu et al. 1986, Yang et al. 1997) and its ability to prevent the oxidation of LDLs in the circulation (Tijburg et al. 1997). Green tea is also known for its anti-mutagenic and anti-carcinogenic effects. Thus, it has been shown that green tea
35 significantly reduces the risk of colorectal, skin and breast cancers (Blot et al. 1997, Conney et al. 1997, Dreosti et al. 1997, Jankun et al. 1997, Ji et al. 1997).

- 3 -

The traditional use of green tea as a diuretic is currently performed in the form of infusions, liquid extracts, extracts of plant powders or extracts in gel capsules or tablets. In these various forms, the green tea, often combined with another diuretic plant, is generally used at a dose corresponding to 1 to 3 g of plant per day.

In the context of screening pharmacological properties of various plants, it has been discovered that extracts of green tea have noteworthy properties which allow them to be used in the treatment of obesity.

The human body continually expends energy in order to function. The origins of this expenditure of energy are threefold: the metabolism, muscular work and thermogenesis, which corresponds to the energy expended by the body to maintain a constant temperature.

The expenditure of energy is compensated for by the energy supplied by the assimilation of foods. If the energy supplied from the dietary ration is strictly identical to the energy expended, the individual maintains a stable weight. If there is an excess supply of energy, the body stores this energy in the form of fats (increase in weight), and if there is a deficit in the supply of energy, the body draws the energy it lacks by burning off the fats stored (loss of weight). However, in this latter situation of an energy deficit encountered in the course of weight-reducing diets, the body reacts to save energy and reduce thermogenesis. This is the control mechanism which accounts for the failure of weight-reducing diets. Specifically, after losing weight for a few weeks, the individual's weight stabilizes. If they wish to continue to slim, they must further reduce their food intake.

The full value of being able continually to increase thermogenesis, in particular in the course of a low-calorie diet during which it is lowered, may thus be appreciated. Various chemical substances stimulate

- 4 -

thermogenesis, such as nicotine, ephedrine, aspirin, caffeine, etc., but none of them has made it possible to produce a medicinal product for treating obesity since the doses required to obtain an increase in thermogenesis entail considerable side effects, which are incompatible with a treatment which is necessarily long-lasting, generally extending over several months.

This objective has been achieved in accordance with the present invention by means of a composition for the curative and prophylactic treatment of obesity, comprising an extract of green tea, *Camellia sinensis*, which is rich in catechols.

The present invention is also directed toward the use of an extract or powder of green tea which has anti-lipase and/or thermogenic properties, for the manufacture of a medicinal product intended for the curative and prophylactic treatment of obesity.

Finally, the present invention relates to a process for the esthetic treatment of a human being in order to enhance his or her figure, characterized in that it involves the oral administration of a catechol-enriched extract of green tea in order to bring about a loss of weight or to maintain a weight level which is as low as desired.

In the context of the present invention, the extract of green tea contains from 20% to 30%, by mass of catechols expressed as epigallocatechol gallate (EGCG).

The content of catechols, expressed as epigallocatechol gallate (EGCG), is, for example, advantageously determined in the context of the present invention by using the analytical method described below.

The process is performed by liquid chromatography.

Solution to be examined: 80 ml of methanol R are added to 0.200 g of extract. The mixture is placed under magnetic stirring for 5 min and then in an

- 5 -

ultrasound bath for 5 min. The resulting mixture is filtered through paper and the volume is made up to 100 ml with the same solvent. This solution is diluted fivefold with methanol R.

5 Caffeine stock solution: 30 mg of caffeine are dissolved in methanol and made up to 100 ml with the same solvent.

Epigallocatechol gallate stock solution: 6 mg of epigallocatechol gallate (EGCG) are dissolved in
10 methanol and made up to 10 ml with the same solvent.

Control solution: 1 ml of each stock solution is taken and made up to 10 ml with the same solvent.

The chromatography can be carried out using:

- 15 - a stainless steel column of length 250 mm and inside diameter 4.6 mm, filled with octadecylsilyl silica gel for chromatography R (5 μ m) and thermostatically maintained at 20°C (Nucleosil C₁₈) and a precolumn having the same characteristics as the column,
- 20 - as mobile phase, at a flow rate of 1 ml/min, a mixture of aqueous 2% V/V glacial acetic acid solution (A) and of acetonitrile (B), the linear elution gradient of which is as follows:

Time (min)	A (%)	B (%)
0	95	5
5	95	5
10	90	10
17	85	15
30	82	18
35	82	18
40	95	5

25

- as detector, a spectrophotometer set at 278 nm.

10 μ l of each of the solutions are injected separately, at least twice. The sensitivity of the
30 detector is adjusted so as to obtain peaks whose height

- 6 -

represents at least 50% of the total scale of the recorder.

The percentage caffeine content is calculated using the following expression:

5

$$\frac{SCE}{SCT} \times \frac{MCT}{MCE} \times 0.05$$

SCE: area of the peak corresponding to caffeine in the chromatogram obtained with the solution to be examined

10 SCT: area of the peak corresponding to caffeine in the chromatogram obtained with the control solution

MCE: test sample of extract in the solution to be examined, expressed in grams

15 MCT: test sample of caffeine in the control solution, expressed in milligrams.

The percentage content of catechols expressed as epigallocatechol gallate (EGCG) is calculated using the following expression:

20

$$\frac{\Sigma SE}{ST} \times \frac{MT}{ME} \times 0.5$$

ΣSE : sum of the areas of the peaks (2-5-6-7-8) corresponding to catechols in the chromatogram obtained with the solution to be examined

25 ST: area of the peak corresponding to the EGCG in the chromatogram obtained with the control solution

ME: test sample of extract in the solution to be examined, expressed in grams

30 MT: test sample of EGCG in the control solution, expressed in milligrams.

According to one particular characteristic of the present invention, the extract of green tea contains from 5% to 10% by mass of caffeine.

35 According to another characteristic of the invention, the extract of green tea has a ratio of the

- 7 -

concentration of catechols to the concentration of caffeine of between 2 and 10.

According to one preferred characteristic of the invention, the extract of green tea is titrated so as to allow the administration of a daily dose of from 250 mg to 500 mg, preferably about 375 mg, of catechols per day, and from 50 mg to 200 mg, preferably about 150 mg, of caffeine per day.

The increase in thermogenesis in rats by an extract of green tea according to the invention was studied according to the following protocol:

The oxygen consumption of rats, maintained in a hermetic chamber for two hours and more, is measured after administering the test product. Since the expenditure of energy is proportional to the oxygen consumption, this technique makes it possible to measure the increase in thermogenesis, the basal metabolism and the muscular work being constant before and after treatment.

The test product was an extract of green tea containing 24.7% catechols and 8.35% caffeine.

The following results were obtained:

Controls: $0.06 \text{ w/kg}^{0.75}$

0.5 mg of extract/kg: $0.45 \text{ w/kg}^{0.75}$

1.0 mg of extract/kg: $0.81 \text{ w/kg}^{0.75}$

2.0 mg of extract/kg: $1.10 \text{ w/kg}^{0.75}$

The increase in thermogenesis in man by an extract of green tea according to the invention was also determined.

A similar study was carried out on 10 volunteers receiving at each meal either 500 mg of an extract of green tea (corresponding to 125 mg of catechols and 50 mg of caffeine), or 50 mg of caffeine, or a placebo.

The total expenditure of energy over 24 h showed a statistically significant increase ($p < 0.01$) in favor of the extract: 9867 kJ compared with 9538 kJ for the placebo and 9599 kJ for caffeine.

- 8 -

These results demonstrate the ability of an extract of green tea according to the invention to significantly increase thermogenesis. This property is not associated with the caffeine content of the extract, since the administration of caffeine alone, at the same dose as that provided by the extract of green tea, does not increase thermogenesis.

Furthermore, the fact that the significant decrease in the Respiratory Quotient is not accompanied by an increase in the urinary excretion of nitrogen, makes it possible to conclude that there has been an increase in the oxidation of lipids, which is the desired aim in any treatment of obesity.

Finally, it has been possible to demonstrate that the extract of green tea according to the invention leads to an inhibition of the digestive lipases. An in vitro study made it possible to demonstrate that the extract of green tea, at a dose of 6 mg of extract per 100 mg of lipids, partially eliminates the emulsification of the lipids, both in the stomach and in the intestine. As it is known that the emulsification of lipids is the essential step in the action of lipases on food lipids, these results may account for the inhibitory ability of digestive lipases.

Another in vitro study, carried out under conditions reproducing the physiological conditions (successive action on triolein of gastric lipase and then of pancreatic lipase) demonstrated that the extract of green tea, at a dose of 6 mg/100 mg of lipids, allows virtually total inhibition of the gastric lipase (89% inhibition) and partial inhibition of the pancreatic lipase (32% inhibition), i.e. a total inhibition of lipolysis of close to 40%.

The use of a powder of green tea which has an intrinsically lower dose of catechols and/or caffeine, but in a larger amount making it possible to manufacture a medicinal product which has anti-lipase

- 9 -

and/or thermogenic properties, obviously also falls within the context of the present invention.

Example of obtaining an extract of green tea

Green tea contains on average 6% to 7% catechols and 2% to 3% caffeine.

In order to obtain the properties of increasing thermogenesis and of inhibiting digestive lipases which are described above, a sufficient supply of catechols is necessary. It is thus necessary to carry out an extraction of the green tea making it possible to obtain an extract which is sufficiently concentrated in catechols.

By way of example, the following extraction process can be used: 1 kg of leaves of green tea are extracted by percolation for 6 to 8 h with 10 kg of 80% ethanol (m/m). After filtration, the extract is concentrated under partial vacuum at a maximum temperature of 60°C. The concentrated extract is then spray-dried at a maximum temperature of 250°C with or without maltodextrin, depending on the plotter specifications selected. This process gives an extract containing 20% to 30% catechols and 5% to 10% caffeine.

This example is not limiting, and other extraction processes for obtaining an extract which is sufficiently rich in catechols can be used, in particular by varying the proportions of water and ethanol, or by using other solvents such as water, ethyl acetate, methanol, etc., alone or in combination. The choice of solvents selected will make it possible to vary the catechol and caffeine contents, the objective being a high catechol content, since the catechols are the main source of the pharmacological properties demonstrated above.

In this context, the use of green tea which has been partially decaffeinated beforehand by any extraction process which does not have a negative effect on the catechols (for example methylene chloride or supercritical carbon dioxide) may be entirely

- 10 -

envisaged in order to obtain a tea extract containing only a small percentage of caffeine.

Without at all wishing to be limited to such an interpretation, it appears likely that the mechanism of activity of the extracts of green tea, which is the subject of the present invention, can be explained as follows. The catechols present in high concentration in the extracts of green tea according to the invention exert an inhibitory effect on catechol-O-methyltransferase (COMT), whereas the caffeine concentration of the extracts of green tea according to the invention acts by inhibiting phosphodiesterases, which leads to a reinforced activity of noradrenalin on thermogenesis.

15

- 11 -

CLAIMS

1. Composition for the curative and prophylactic treatment of obesity, comprising an extract of green tea rich in catechols.
2. Composition according to Claim 1, characterized in that the extract of green tea contains from 20% to 30% by mass of catechols expressed as epigallocatechol gallate (EGCG).
3. Composition according to either of Claims 1 and 2, characterized in that the extract of green tea contains from 5% to 10% by mass of caffeine.
4. Composition according to one of Claims 1 to 3, characterized in that the extract of green tea has a ratio of the concentration of catechols to the concentration of caffeine of between 2 and 10.
5. Composition according to one of Claims 1 to 4, characterized in that the extract of green tea is titrated so as to allow the administration of a daily dose of from 250 mg to 500 mg, preferably about 375 mg, of catechols per day, and from 50 mg to 200 mg, preferably about 150 mg, of caffeine per day.
6. Use of an extract or powder of green tea for the manufacture of a medicinal product which has anti-lipase and/or thermogenic properties, and which is intended for the curative and prophylactic treatment of obesity.
7. Use according to Claim 6, characterized in that the extract of green tea contains from 20% to 30%, by mass of catechols expressed as epigallocatechol gallate (EGCG).
8. Use according to either of Claims 6 and 7, characterized in that the extract of green tea contains from 5% to 10% by mass of caffeine.
9. Use according to one of Claims 6 to 8, characterized in that the extract of green tea has a ratio of the concentration of catechols to the concentration of caffeine of between 2 and 10.

- 12 -

10. Use according to one of Claims 6 to 9, characterized in that the extract of green tea is titrated so as to allow the administration of a daily dose of from 250 mg to 500 mg, preferably about 375 mg, of catechols per day, and from 50 mg to 200 mg, preferably about 150 mg, of caffeine per day.

11. Process for the esthetic treatment of a human being in order to enhance his or her figure, characterized in that it involves the oral administration of a catechol-enriched extract of green tea in order to bring about a loss of weight or to maintain a weight level which is as low as desired.

12. Process according to Claim 11, characterized in that the extract of green tea contains from 20% to 30%, by mass of catechols expressed as epigallocatechol gallate (EGCG).

13. Process according to either of Claims 11 and 12, characterized in that the extract of green tea contains from 5% to 10% by mass of caffeine.

14. Process according to one of Claims 11 to 13, characterized in that the extract of green tea has a ratio of the concentration of catechols to the concentration of caffeine of between 2 and 10.

15. Process according to one of Claims 11 to 14, characterized in that the extract of green tea is titrated so as to allow the administration of a daily dose of from 250 mg to 500 mg, preferably about 375 mg, of catechols per day, and from 50 mg to 200 mg, preferably about 150 mg, of caffeine per day.

ORIGINAL

CABINET REGIMBEAU
PATENT ATTORNEYS
26, Avenue Kléber
75116 PARIS